Ex vivo expansion of lung cancer-derived disseminated cancer cells from lymph nodes identifies cells associated with metastatic progression

The cellular basis of the apparent aggressiveness in lung cancer is poorly understood but likely associated with functional or molecular features of disseminated cancer cells (DCCs). DCCs from epithelial cancers are mostly detected by antibodies directed against histogenetic markers such as cytokera...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cancer 2023-11, Vol.153 (10), p.1854-1867
Main Authors: Treitschke, Steffi, Weidele, Kathrin, Varadarajan, Adithi Ravikumar, Feliciello, Giancarlo, Warfsmann, Jens, Vorbeck, Sybille, Polzer, Bernhard, Botteron, Catherine, Hoffmann, Martin, Dechand, Vadim, Mederer, Tobias, Weber, Florian, Werner-Klein, Melanie, Robold, Tobias, Hofmann, Hans-Stefan, Werno, Christian, Klein, Christoph A
Format: Article
Language:English
Subjects:
Cancer
Cell culture
Cell suspensions
Copy number
Cytokeratin
ErbB-1 protein
Genotypes
Lung cancer
Lymph nodes
Medical research
Metastases
Metastasis
p53 Protein
Spheres
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The cellular basis of the apparent aggressiveness in lung cancer is poorly understood but likely associated with functional or molecular features of disseminated cancer cells (DCCs). DCCs from epithelial cancers are mostly detected by antibodies directed against histogenetic markers such as cytokeratin or EpCAM. It has been argued that marker-negative metastatic founder cells might escape detection. We therefore used ex vivo sphere formation for functional detection of candidate metastasis founders. We generated cell suspensions from 199 LN samples of 131 lung cancer patients and placed them into non-adherent cell culture. Sphere formation was associated with detection of DCCs using EpCAM immunocytology and with significantly poorer prognosis. The prognostic impact of sphere formation was strongly associated with high numbers of EpCAM-positive DCCs and aberrant genotypes of expanded spheres. We also noted sphere formation in patients with no evidence of lymphatic spread, however such spheres showed infrequent expression of signature genes associated with spheres from EpCAM-positive samples and displayed neither typical lung cancer mutations (KRAS, TP53, ERBB1) nor copy number variations, but might be linked to disease progression >5 years post curative surgery. We conclude that EpCAM identifies relevant disease-driving DCCs, that such cells can be expanded for model generation and that further research is needed to clarify the functional and prognostic role of rare EpCAM-negative sphere forming cells.
ISSN:0020-7136
1097-0215
DOI:10.1002/ijc.34658